已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).

医学 肉瘤 癌症研究 软组织肉瘤 放射治疗 平方毫米 体内 生物标志物 肿瘤科 病理 内科学 基因 生物 生物化学 生物技术
作者
M.X. Welliver,Brian Andrew Van Tine,Peter Houghton,Michelle A. Rudek,Raphael E. Pollock,John M. Kane,Gary K. Schwartz,Peixin Zhang,David G. Kirsch,Paul E. Wakely,Steve Jiang,Shahanawaz Jiwani,Alan Rogers,Dian Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (15_suppl): TPS11076-TPS11076 被引量:8
标识
DOI:10.1200/jco.2019.37.15_suppl.tps11076
摘要

TPS11076 Background: Over-expression of mdm2 is a major block to p53 activation in soft tissue sarcoma (STS). AMG-232 specifically inhibits human MDM2-p53 interactions in vitro and in vivo, thereby activating p53. Resistance mechanisms to MDM2 inhibition by AMG-232 is through accumulation of MDM2 and MDMX. However, DNA damaging agents, such as radiotherapy (RT), promote MDMX degradation and lead to sustained p53 activation, which is critically important for radiation-induced tumor cell killing in STS. Indeed, preclinical studies reveal that AMG-232 synergizes with RT in vitro and in vivo when treating STS with wild type (WT) P53 gene . Since a majority of STS harbor WT TP53 gene and RT is part of the standard of care in treating STS; it is the next rational step to test the safety and efficacy of combination of AMG-232 and RT followed by surgery. In this clinical trial, we hypothesize that preoperative AMG-232 plus RT is safe and well tolerated in 2 separate cohorts: (A) extremity and body wall; (B) abdomen/pelvis/retroperitoneum. Methods: A key feature of this trial is to incorporate TP53 NGS sequencing result as one of the eligibility criteria. Adult patients with pathologically proven grade 2-3 STS with size ≥ 5 cm are eligible to enroll if there is a planned definitive surgical resection of the primary tumor. There must be sufficient tissue to submit to central laboratory for NGS sequencing of the TP53 gene, which is an integral biomarker. Only those with tumors harboring WT p53 gene will be allowed to continue protocol treatment. The primary objective is to evaluate the safety and tolerability of AMG-232 in combination with standard-dose RT in STS in two separate cohort; as well as to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of AMG-232 in combination with RT. We define DLT as grade 4-5 toxicities attributable to AMG-232 for up to 4 weeks after the completion of combination treatment (prior to surgery) as well as any AMG-232 related grade 3 toxicity that should lead to > 2 weeks treatment delay or ≥ two dose reductions. There are 3 dose levels for AMG-232: dose level 1 is 120 mg daily for 3 days per week; dose level 2 is 120 mg daily 4 days per week and dose level 5 is 120 mg daily 5 days a week. If patients did not tolerate dose level 1, AMG-232 will be de-escalated to a lower level, which is 120 mg daily 2 days a week. The trial was open since 11/2017; 3 patients have been enrolled to cohort A and 2 patients in cohort B at dose level 1. The first patient has a tumor with WT p53 gene and has completed protocol treatment safely. Clinical trial information: NCT03217266.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ff完成签到,获得积分10
1秒前
水晶鞋完成签到 ,获得积分10
1秒前
青糯完成签到 ,获得积分10
1秒前
现代雁桃完成签到,获得积分20
2秒前
nn完成签到,获得积分10
3秒前
量子星尘发布了新的文献求助10
3秒前
minnie完成签到 ,获得积分10
3秒前
椿iii完成签到 ,获得积分10
4秒前
C_Cppp完成签到 ,获得积分10
4秒前
jhlz5879完成签到 ,获得积分10
5秒前
怕黑钢笔完成签到 ,获得积分10
6秒前
WHY完成签到 ,获得积分10
6秒前
rpe完成签到,获得积分10
6秒前
橘子屿布丁完成签到,获得积分10
7秒前
欣慰的舞仙完成签到,获得积分10
8秒前
KK完成签到,获得积分10
9秒前
10秒前
LJL完成签到 ,获得积分10
10秒前
王晓静完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助30
12秒前
温柔的柠檬完成签到 ,获得积分10
12秒前
蔚欢完成签到 ,获得积分10
12秒前
独特的娩完成签到 ,获得积分10
13秒前
cheng完成签到 ,获得积分10
14秒前
Cheng完成签到 ,获得积分10
15秒前
39完成签到,获得积分10
15秒前
vicky完成签到,获得积分20
15秒前
16秒前
欣喜的书芹完成签到,获得积分10
17秒前
wangye完成签到 ,获得积分10
19秒前
打打应助dengxu采纳,获得10
20秒前
Ren完成签到 ,获得积分10
20秒前
唯一完成签到 ,获得积分10
20秒前
哈哈哈完成签到 ,获得积分10
20秒前
123完成签到 ,获得积分10
21秒前
慕斯完成签到,获得积分10
21秒前
学霸完成签到 ,获得积分10
22秒前
量子星尘发布了新的文献求助10
22秒前
粉色娇嫩完成签到 ,获得积分10
23秒前
李鱼丸完成签到,获得积分10
23秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
Statistical Methods for the Social Sciences, Global Edition, 6th edition 600
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
ALUMINUM STANDARDS AND DATA 500
Walter Gilbert: Selected Works 500
An Annotated Checklist of Dinosaur Species by Continent 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3666266
求助须知:如何正确求助?哪些是违规求助? 3225309
关于积分的说明 9762492
捐赠科研通 2935243
什么是DOI,文献DOI怎么找? 1607513
邀请新用户注册赠送积分活动 759242
科研通“疑难数据库(出版商)”最低求助积分说明 735185

今日热心研友

NZH
20
nenoaowu
2
MchemG
2
pluto
10
Xiaoxiao
10
安静的远山
1
注:热心度 = 本日应助数 + 本日被采纳获取积分÷10